Velcade
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Velcade (bortezomib; Takeda/Johnson & Johnson) is an intravenously or subcutaneously administered 26S proteasome inhibitor that affects multiple signaling cascades and induces cell death. In preclinical studies, Velcade has been shown to induce apoptosis and sensitize tumor cells to chemotherapy or radiation.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Velcade : Multiple myeloma
23 Velcade : NHL: Mantle cell lymphoma (MCL)
LIST OF FIGURES
12 Figure 1: Velcade for multiple myeloma – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Velcade for multiple myeloma
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Velcade for multiple myeloma
17 Figure 4: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
26 Figure 5: Velcade for mantle cell lymphoma – SWOT analysis
27 Figure 6: Datamonitor Healthcare’s drug assessment summary of Velcade in mantle cell lymphoma
28 Figure 7: Datamonitor Healthcare’s drug assessment summary of Velcade in mantle cell lymphoma
LIST OF TABLES
5 Table 1: Velcade drug profile
7 Table 2: Velcade pivotal trial data in multiple myeloma
10 Table 3: Velcade late-phase trial data in multiple myeloma
18 Table 4: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
20 Table 5: Patients treated with Velcade in the US, Japan, and five major EU markets, by country, 2017–26
24 Table 6: Velcade drug profile
25 Table 7: Velcade pivotal trial data in mantle cell lymphoma
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Thalomid 
Sign up to the